

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 35/74, C12N 1/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/55131</b> <b>(43) International Publication Date:</b> 10 December 1998 (10.12.98)
<b>(21) International Application Number:</b> PCT/SE98/01041 <b>(22) International Filing Date:</b> 2 June 1998 (02.06.98) <b>(30) Priority Data:</b> 9702083-8      2 June 1997 (02.06.97)      SE <b>(71) Applicant (for all designated States except US):</b> ESSUM AB [SE/SE]; Glimmervägen 5 E, S-907 40 Umeå (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GRAHN HÅKANSSON, Eva [SE/SE]; Nygatan 74, S-903 31 Umeå (SE). HÅKANSSON, Stellan [SE/SE]; Nygatan 74, S-903 31 Umeå (SE). <b>(74) Agent:</b> AWAPATENT AB; P.O. Box 5117, S-200 71 Malmö (SE).		<b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>In English translation (filed in Swedish).</i> <i>With an indication in relation to deposited biological</i> <i>material furnished under Rule 13bis separately from the</i> <i>description.</i>
<b>(54) Title:</b> PHARMACEUTICAL PREPARATION COMPRISING LACTOBACILLUS CASEI RHAMNOSUS  <b>(57) Abstract</b>  A pharmaceutical preparation for prophylaxis against and/or treatment of gastrointestinal disorders in man and animals is described, the preparation comprising the strain Lactobacillus casei rhamnosus LB21 and/or one or more variants thereof with an essentially similar function in at least one pharmaceutically acceptable carrier medium, in which the microorganism maintains its viability.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL PREPARATION COMPRISING LACTOBACILLUS  
CASEI RHAMNOSUS

The present invention relates to a pharmaceutical preparation for prophylaxis against and/or treatment of gastrointestinal disorders in man and animals.

Background

5       A health problem which is widely spread in many contexts is diarrhoea and other enteric disorders caused by various pathogenic microorganisms. The problems are particularly common in people that have been treated with antibiotics or radiation in cancer treatment, in people  
10       suffering from stress, in tourists travelling abroad, and in day-care centres. Examples of intestinally pathogenic bacteria which thus cause diarrhoea are Salmonella, Shigella, Yersinia, E.coli, Pseudomonas, Clostridium difficile and sordelli, Stafylococcus aureus, Klebsiella,  
15       Helicobacter pyroli and Campylobacter.

      It has been widely known for a long time that microorganisms affect each other positively or negatively by promoting or inhibiting each other's growth. This interference phenomenon has been studied above all in the skin  
20       flora, the pharynx and the intestines of man. The underlying mechanisms are not fully known, but it has been found that the normal bacterial flora is very important in the defence against pathogenic bacteria. Invading bacteria are inhibited by the bacteria in the normal flora  
25       in different ways, one of which is the production of antibiotic-like substances, so-called bacteriocins. In contrast to antibiotics, the bacteriocins have in most cases a very selective effect on a group of bacteria, but do not affect the remaining bacterial flora. The possibility  
30       of administering harmless bacteria with such a specific effect to patients suffering from infection has not only been discussed but has also been made use of to some extent. It goes without saying that the administered bacteria must be able to establish themselves in the

environment that is to be affected. For instance, this has been the idea of giving sour milk to patients having a disturbed intestinal flora, caused by severe diarrhoea after being treated with antibiotics. However, it has not  
5 been scientifically analysed what has happened in the intestinal flora, and the effect, if any, has in most cases been uncertain. This has probably been due to the fact that no colonisation has taken place in the intestines, or that the added bacteria had no possibility of  
10 interfering with the bacteria causing diarrhoea. Experiments have also been made to replace the bacterial flora with harmless microorganisms in the nasal mucous membrane, the skin and the pharynx, and these experiments have proved that a so-called recolonisation is possible  
15 and may give the intended effects.

As mentioned above, the experiments that have been made to administer bacteria to patients suffering from various disorders, caused by pathogenic microorganisms, have in most cases given inconclusive results. Apparently  
20 the knowledge of which bacterial strains are best suited to achieve colonisation and interference has not been sufficient.

By working under defined conditions, it has in recent years become possible to establish important  
25 basic principles of mechanisms which control the interaction between microorganisms and also to develop methods for studying this interaction. This has opened new possibilities of interfering with this interaction in a meaningful, reproducible manner and, consequently, also to  
30 therapeutically-prophylactically utilise this in the treatment of infections.

In newborn babies, it is Lactobacillus strains which together with Bifido bacteria first colonise the sterile intestines. Also in adults, Lactobacillus is a dominating  
35 normal flora in the intestines. Many Lactobacillus strains in fact produce lactic acid, acetic acid and hydrogen peroxide, which has an inhibitory effect on

potentially intestinally pathogenic bacteria. Some of them have effect against specific strains, whereas others have a wider inhibitory effect.

The significance of *Lactobacillus* strains in the intestinal flora has been demonstrated in many different studies (see the basic literature references 1-8). For instance, it has been shown that certain *Lactobacillus* strains protect against colonisation of pathogenic bacteria, produce bacteriocins and other antimicrobial components, stimulate the immune system, decrease the risk of tumours and colon cancer, reduce the serum cholesterol content, improve the gastrointestinal mobility of old people, improve the tolerance of lactose etc. There are also studies where it has not been possible to show these effects, depending on the fact that all *Lactobacillus* strains do not function in the tested respect. In some studies, use has been made of an unsuitable *Lactobacillus* preparation, e.g. freeze-dried in pulverulent state or as uncoated capsules.

WO 96/38159 (Lafor Lab Ltd) discloses a pharmaceutical composition for treatment of antibiotic-associated diarrhoea, said composition containing, inter alia, viable *Lactobacillus rhamnosus* strains.

Japanese Patent Application 172,949 by Jakult Honsa KK discloses, among other things, *Lactobacillus rhamnosus* and *casei* as an active ingredient in an anti-allergic agent.

WO 93/01823 concerns a process for isolating of a strain of *Lactobacillus* having the ability of colonising in human intestines. For example, the strain of *L. casei* sp. *rhamnosus* 271 has been isolated and is said to be useful for prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition. The strain at issue has been isolated from the intestines in adults.

EP-A-0 271 364 relates to a preparation for treatment or prophylaxis of enteric disorders in animals. This

preparation comprises one or more lactic acid bacteria selected from the phenotypes of, inter alia, *Lactobacillus casei* spp. *rhannosus*. The preparation is a non-specific mixture of a plurality of strains and besides is not  
5 intended for use in man. The strains at issue seem to have been isolated from cattle and sheep and are thus not applicable to man. Moreover, experiments have only been made on cattle and sheep.

DT-A1-2,421,066 relates to a preparation for  
10 reestablishing a disturbed intestinal flora to a normal state, the preparation comprising a mixture of bifido bacteria and possibly also a *Lactobacillus casei* var. *rhannosus* strain.

In our analyses of the interaction between different  
15 bacteria, we have studied, inter alia, how certain *Lactobacillus* strains can counteract diarrhoea which has occurred owing to the intake of antibiotics and prevent the growth of pathogenic bacteria such as *Helicobacter*. On a laboratory scale, cultures of *Lactobacillus* have  
20 been tested, from which a great number of clones with varying biological properties have been isolated. One of these, *Lactobacillus casei rhannosus* LB21, below also referred to as "LB21", has been isolated from faeces of infants and has proved to have a particularly pronounced  
25 inhibitory effect on the majority of the bacteria that are important to different types of infections in man, such as *Staphylococcus aureus*, different species of *Salmonella*, *Shigella*, *Pseudomas*, *Klebsiella-Enterobacter*, *Campylobactus*, *Clostridium difficile*, *Helicobacter pylori*  
30 etc. The strongly inhibitory effect of precisely LB21 on intestinally pathogenic bacteria is probably due to the fact that it produces a specific low-molecular protein or a specific low-molecular peptide, which is thermally stable, has a molecular weight below 5000 Daltons and  
35 which in a unique fashion has a detrimental effect on intestinally pathogenic bacteria.

However, none of the above-mentioned publications describes the specific strain *Lactobacillus casei rhamnosus* LB21, which has been isolated from faeces of infants and which has a considerably improved effect on gastrointestinal disorders compared with closely related strains.

#### Object of the Invention

The object of the present invention is to alleviate the above-mentioned health problems more effectively than allowed by prior-art methods of treatment. This object is achieved by a pharmaceutical preparation of the type mentioned by way of introduction, which in addition has the features defined in the characterising clause of appended claim 1. Preferred embodiments are stated in the appended subclaims.

#### Description of the Invention

The present invention relates to a pharmaceutical preparation for prophylaxis against and/or treatment of gastrointestinal disorders in man and animals, said preparation being characterised in that it comprises a viable microorganism strain in the form of the *Lactobacillus casei rhamnosus* strain LB21 and/or one or more variants thereof with an essentially similar function, in at least one pharmaceutically acceptable carrier medium, in which the microorganism retains its viability. More specifically, the present invention relates to a pharmaceutical preparation for prophylaxis against and/or treatment of, inter alia, antibiotic-associated diarrhoea, helicobacter infection in the stomach, tourist diarrhoea and stress-induced gastrointestinal disorders.

Moreover, the present invention concerns the *Lactobacillus casei rhamnosus* strain NCIMB 40564, which is capable of preventing and/or curing gastrointestinal disorders in man and animals, and which has been isolated from faeces of an approx. 1-8-day-old infant.

The inventive pharmaceutical preparation contains the microorganism strain *Lactobacillus casei rhamnosus*

LB21 or the variant thereof in an amount of  $10^2$ - $10^{12}$ , preferably  $10^6$ - $10^{10}$ , colony-forming units per ml of ready-to-use preparation.

By the expression colony-forming units is meant the  
5 number of colonies containing one or more bacteria growing on a substrate.

By the expression helicobacter infection is meant symptoms of gastric ulcer where Helicobacter has been identified to be present in the stomach or the upper  
10 part of the small intestine.

By the expression tourist diarrhoea is meant diarrhoea occurring as the gastrointestinal flora changes, for instance, abroad, and also in case of infection caused by e.g. Salmonella and E.coli.

15 By the expression stress-induced gastrointestinal disorders is meant imbalance in the gastrointestinal flora causing stomach-ache, diarrhoea, gas formation etc.

In a preferred embodiment of the invention, the carrier of LB21 is a soured or fermented milk product, such  
20 as soured milk, yoghurt, milk, or it is fruit juice, ice-cream, soup or fruit drinks. The strain of bacteria can be used as starting culture in the preparation of such milk products, resulting in soured or fermented milk products having an increased amount of the advantageous  
25 strain. Of course it is also possible to add LB21 to prepared milk products or to fruit juice, soup or ice-cream to obtain in this manner a greater amount of desirable bacteria in the medium. This embodiment is highly important since the thus obtained preparation is a wholesome  
30 and appreciated foodstuff. Such a preparation can be given prophylactically or curatively against diarrhoea and other intestinal infections that frequently affect infants. Besides it can be given to people treated with antibiotics or radiation in cancer treatment, to people  
35 having a helicobacter infection in the stomach and to tourists travelling abroad, where a bacterial flora that



is unfamiliar to the gastrointestinal duct is frequently encountered.

The preparation can also be present in dry form for oral administration, for instance, in the form of capsules, tablets or powder or in the form of a suspension, optionally frozen, such as NaCl solution, glucose solution or skim milk. The carrier media here used are of a conventional type and well known to those skilled in the art. The capsules can be of a type resistant to gastric juice, such that the bacteria are protected against the gastric juice and only released in the intestines. For the same reason, tablets can be administered with a prior-art type of coating resistant to gastric juice. Powders can be intended to be stirred into an aqueous liquid before administration, for instance, water, fruit juice or some milk product.

The preparation has thus been found to have a particularly great potential as a prophylactic agent against and/or an agent for treating antibiotic-associated diarrhoea.

The preparation can also advantageously be used for prophylaxis against and/or treatment of helicobacter infection in the stomach and the upper small intestine in man and animals, but also against so-called tourist diarrhoea and stress-induced gastric disorders.

In the pharmaceutical preparation according to the present invention, some other lactic acid bacterium can possibly also be incorporated, such as one or more Lactococcus or Lactobacillus strains, but preferably the strain of Lactococcus lactis L1A is also incorporated.

The pharmaceutical preparation according to the present invention has also been found to be particularly advantageous in prophylaxis and/or treatment of children in the following situations.

a) Newborn babies and prematurely born babies in need of intensive care.

Such intensive care can result in the fact that the normal colonisation of the intestines with Lactobacilli and bifido bacteria does not take place, which increases the risk of pathogenic bacteria dominating. This also  
5 increases the risk of infections and use of antibiotics. The adding of LB21 can normalise the intestinal flora in these babies and counteract the unfavourable development as described above.

10 b) Babies exposed to an increased risk of getting type 1 diabetes, celiaki (gluten allergy) and various autoimmune conditions.

A factor causing these disorders probably is disturbed immune control in the intestines such that antigens (substances not occurring naturally in the body)  
15 from food, intestinal bacteria, virus or other micro-organisms may cause an immune reaction against the own tissues of the body. Adding LB21 can normalise the intestinal flora and, thus, counteract the occurrence of these disorders.

20 c) Children having undergone an operation for bile duct atresia (congenital malformation with complete or partial loss of bile ducts in and/or outside the liver) and children having undergone a liver transplant.

These categories of children run an increased risk  
25 of being stricken with infections affecting liver/bile ducts after the operation. The supplying of LB21 can reduce the risk of such complications by inhibiting the growth of the bacteria that usually cause these types of infections.

30 The inventive pharmaceutical preparation is also useful in connection with cytotoxic treatment. Patients with cancer diseases are frequently treated with cytotoxins which have a negative effect on the function of the intestines and have a detrimental effect on the  
35 structure and new growth of the intestinal mucous membrane. In consequence, this type of treatment often causes a reduced assimilation of nutrients and diarrhoea.

A further consequence is that intestinal bacteria can spread to the blood vessels through the weakened intestinal mucous membrane and cause serious infections. This leads to an increased consumption of antibiotics, which  
5 in turn further deteriorates the function of the intestines and may imply that various intestinal bacteria develop resistance to antibiotics.

By supplying LB21 in connection with the treatment with cytotoxins, the negative effects on the function and  
10 structure of the intestinal mucous membrane can be reduced, thereby reducing the risk of serious infections caused by bacteria in the intestines.

Moreover, the pharmaceutical preparation according to the present invention is useful for preventing allergy  
15 in children, e.g. atopic eczema, and for preventing and treating constipation, above all in old people.

When the pharmaceutical preparation according to the invention is intended for treatment of animals, the carrier is a suitable feedstuff, such as in the form of  
20 whey, dry fodder or a concentrated suspension.

The microorganism should be stored in a freeze-dried state, preferably in skim milk in a dark and dry place, but also frozen at a temperature of about  $-70^{\circ}\text{C}$ .

The necessary dose of the inventive preparation  
25 can be adjusted in dependence on such factors as the patient's age and condition, as well as the type and degree of difficulty of the illness. It is within the competence of a person skilled in the art to determine a suitable dose against this background. A further advantage of the invention is that a great overdose of the  
30 pharmaceutical operation hardly means a risk to the patient.

#### Inventive microorganism

The above-mentioned microorganism strain *Lactobacillus casei rhamnosus* LB21 was isolated as one of about  
35 hundred *Lactobacillus* strains from faeces of an approx. 5-day-old healthy baby and was then selected to be the

most effective strain for the inventive purpose. It is very important that LB21 be isolated from the baby in the first week, such as from the first to the eighth day of living, preferably approximately on the fifth day of living. LB21 is distinguished from other *Lactobacillus casei rhamnosus* strains by using pulsed field electrophoresis (PFGE) according to the Fasola and BioRad method. LB21 has previously not been isolated and defined and thus is a previously completely unknown *Lactobacillus casei rhamnosus* strain, which has been found to have particularly favourable effects in the above-mentioned health problems and states of ill-health.

The following Table shows test results from the initial stage of selection, where LB21 is compared with other *Lactobacillus* strains which have been isolated from faeces of babies in respect of the inhibitory effect on several pathogens.

Interference Table

Pathogen	LB 6	LB 8	LB 14	LB 18	LB 21	LB 27	LB 32
E.coli	4/5	1/5	0/5	2/5	5/5	0/5	1/5
Klebsiella	2/5	2/5	1/5	2/5	5/5	1/5	3/5
Ent.cocc	0/5	0/5	0/5	1/5	3/5	0/5	1/5
GBS	2/5	0/5	0/5	2/5	5/5	0/5	2/5

As mentioned above, the LB21 strain is included as an active ingredient in the inventive preparation and was deposited on 11 June 1993 at The National Collection of Industrial and Marine Bacteria (NCIMB), 23 St. Machar Drive, Aberdeen AB2 1RY, Great Britain. Its accession number is NCIMB 40564. It should be noted that the strain was deposited with the identification reference *Lactobacillus casei rhamnosus* L20 05, but that the usual designation of the strain has later been changed to *Lactobacillus casei rhamnosus* LB21. The strain is typified or classified according to the API 50CH-system (API-System -

La Balme les Grottes - 38390 Montalieu - Vercieu), which is apparent from the following Typifying Table.

API 50 CL

5 37°C, CO<sub>2</sub> blood agar

	<u>Compound</u>	<u>Code</u>	<u>24 h</u>	<u>48 h</u>
	0 Check	-	-	-
	1 Glycerol	-	-	-
	2 Erythritol	-	-	-
10	3 D-arabinose	-	-	-
	4 L-arabinose	-	-	-
	5 Ribose	+	+	+
	6 D-xylose	-	-	-
	7 L-xylose	-	-	-
15	8 Adonitol	-	-	-
	9 $\beta$ -methylxyloside	-	-	-
	10 Galactose	+	+	+
	11 D-glucose	+	+	+
	12 D-fructose	+	+	+
20	13 D-mannose	+	+	+
	14 L-sorbose	-	-	-
	15 Rhamnose	G	G	G
	16 Dulcitol	+	G	+
	17 Inositol	-	-	-
25	18 Mannitol	+	+	+
	19 Sorbitol	+	G	+
	20 $\alpha$ -methyl-D-mannoside	-	-	-
	21 $\alpha$ -methyl-D-glucoside	-	-	-
	22 N-acetylglucoseamine	+	+	+
30	23 Amygdalin	G	-	G
	24 Arbutin	+	-	+
	25 Esculin	+	+	+
	26 Salicin	+	+	+
	27 Cellobiose	+	-	+
35	28 Maltose	-	-	-
	29 Lactose	+	+	+

12

	<u>Compound</u>	<u>Code</u>	<u>24 h</u>	<u>48 h</u>
	30 Melibiose	-	-	-
	31 Saccharose	-	-	-
	32 Trehalose	+	+	+
5	33 Inulin	-	-	-
	34 Melezitose	+	-	+
	35 D-raffinose	-	-	-
	36 Amidon	-	-	-
	37 Glycogen	-	-	-
10	38 Xylitol	-	-	-
	39 $\beta$ -gentiobiose	G	-	G
	40 D-turanose	-	-	-
	41 D-lyxose	-	-	-
	42 D-tagatose	+	+	+
15	43 D-fucose	-	-	-
	44 L-fucose	-	-	-
	45 D-arabitol	-	-	-
	46 L-arabitol	-	-	-
	47 Gluconate	G	G	G
20	48 2-cetogluconate	-	-	-
	49 5-cetogluconate	-	-	-

G = green colour

+ = complete change to yellow colour

25 - = original blue-lilac colour

It is here important to emphasise that there is a great difference between different *Lactobacillus* strains, as is also the case in the subspecies *Lactobacillus casei* rhamnosus (LB21). LB21 in the pharmaceutical preparation according to the present invention has certainly been identified as a *Lactobacillus casei* rhamnosus strain, but this is far from meaning that the strain at issue is identical with or similar to other *Lactobacillus casei* rhamnosus strains described in the literature, such as in WO 93/01823. These subspecies grow, for instance, differently well in oxygen environment and at different tempe-

ratures. It is evident that it is not a matter of identical strains, and a detailed characterisation of the respective subspecies (cf. above) shows that they have different properties, which a person skilled in the art realises. A great difference is, for instance, that LB21 has been isolated from faeces of a baby, whereas the strain 271 in WO 93/01823 has been isolated from the intestines of adults.

The pharmaceutical preparation according to the present invention, however, also comprises variants of the *Lactobacillus casei rhamnosus* strain LB21 having an essentially similar function, i.e. a capability of preventing and/or curing the above-mentioned gastrointestinal disorders, e.g. mutants.

#### Performed Experiments

##### Passage through the Gastrointestinal Duct

A requirement for probiotic strains of lactic acid bacteria, such as LB21 in the inventive preparation, to be able to act in the small and thick intestine of man and animals is that they must survive the passage through the acid environment of the stomach. A study has been made to prove that *Lactobacillus casei rhamnosus* LB21 could survive the passage through the stomach and be found in the faeces of healthy volunteers. Moreover, we have studied for how long this strain could be found in the faeces after the subjects of the experiment had discontinued the oral intake of the same.

In a part experiment A, 25 healthy voluntary people supplied a sample of faeces in a sterile plastic tube. The sample was stored in a cold place (4°C max) up to the occasion of cultivation. Before cultivation, the sample was mixed into a 0.9% salt solution at a ratio of 1:10. Then 10 µl of the sample was cultured on Rogosa plates with 128 µ/ml vancomycin. The plates were incubated at 37°C in CO<sub>2</sub> environment and were read after 48 h. The limit for participating in part experiment B was set

to be at most  $4 \times 10^4$  colony-forming units of vancomycin-resistant lactobacilli per g of faeces.

In part experiment B, 13 of the 25 above-mentioned people participated, having a relatively vancomycin-sensitive lactobacilli flora in the intestines. The objects  
5 were instructed not to eat foodstuff containing lactobacilli from 2 weeks before the start of the study including the last day of the study. Each object had in connection with a meal 10 ml salt-solution with  $10^{11}$  colony-  
10 forming units of viable LB21 a day for 5 days. These objects supplied a sample of faeces the day before the intake of lactobacilli (zero sample) and then from the 4th day of the LB21 intake up to and including 12 days after the completed cure. Sampling and cultivation of  
15 samples were carried out according to the same method as in part experiment A. The identification of *Lactobacillus casei rhamnosus* LB21 was carried out by means of gram colouring and API classification (CHL-media).

It should be noted that object No. 8 took penicillin  
20 in the course of the study. This object therefore took LB21 for 10 days starting at the same time as the rest of the group of objects.

Part experiment B was interrupted 12 days after the intake of LB21 had ceased. This took place although LB21  
25 could still be found in the faeces of 4 of 13 objects. In the remaining 9 objects, LB21 could be isolated from the faeces on average 5 days after the intake had ceased. In object No. 8 taking penicillin, LB21 was found in the faeces during the entire penicillin cure and 2 days after  
30 the intake had ceased. In the samples of faeces, LB21 was found in the order of  $1 \times 10^3$  to  $5 \times 10^5$  colony-forming units per g of faeces.



15

		Number of days after the cessation of the treatment LB21 present in faeces
	Object	
	1	3
5	2	6
	3	3
	4	12
	5	12
	6	3
10	7	5
	8	2
	9	7
	10	12
	11	3
15	12	7
	13	12

Summing up, it could be established that the Lacto-  
 bacillus casei rhamnosus strain LB21 survived the passage  
 20 through the stomach and could be found in the faeces of  
 all objects, also the object who had undergone a penicil-  
 lin treatment. 4 of the 13 objects still had LB21 in the  
 faeces 12 days after the cessation of oral intake of  
 LB21. The remaining 9 objects still had LB21 on average  
 25 5 days after the intake of LB21 had ceased. The average  
 number for the entire group of 13 objects was 6 days.

#### Inhibitory Effect of Lactobacillus casei rhamnosus LB21

The above-mentioned lactic acid bacterium LB21 has  
 been tested for its inhibitory effect on a large number  
 30 of intestinally pathogenic bacteria. It has been found to  
 have a satisfactory inhibitory effect, and an experiment  
 was also carried out for the purpose of investigating if  
 it could also inhibit E.coli 0-157, Clostridium difficile  
 and Helicobacter pylori.

35 Two strains of E.coli 0-157, one being tox- and  
 the other being tox+, were isolated from patients. Five  
 strains of Clostridium difficile from patients suffering

from antibiotic-associated diarrhoea, and three strains of *Helicobacter pylori* from clinical material (biopsies) were also tested. In the performed interference test use was made of the agar layer method, which was adjusted to the bacteria tested. This method means that the Lactobacillus strains are cultivated in MRS broth (Merck) at 37°C in 5% CO<sub>2</sub> overnight. Each strain was then moulded separately into MRS agar (25 ml agar). The agar plates were incubated in the above-mentioned conditions for 24 h. A new agar layer (M17 agar (Merck), 25 ml) or blood agar (BHI + horse blood) was poured over the first layer, and the second layer is then allowed to solidify for 4 h. The test bacteria were then cultivated separately in TY medium (Holm, S E and Falsen, E, APMIS 1967; 69, 264) at 37°C. The bacteria were passed to Bertani troughs (0.25 ml, 10<sup>6</sup> bacteria per ml). The bacteria were diluted to 1:10 in NaCl in a new Bertani trough. From these troughs the test strains (25 per trough) were then stamped on the agar plate by means of a Steers steel pin replicator. The plates were incubated at 37°C for *E. coli*, at 37°C and anaerobically for *Clostridium difficile* and at 37°C in microaerophilic environment for *Helicobacter pylori*. (Steers E et al, J. Antibiot. Chemoter. 179; 9, 307). For checking, plates without LB were used.

25       The LB21 strain inhibited all the tested bacteria.

      The final result showed that the LB21 strain had an excellently satisfactory inhibitory effect on these intestinal pathogens, which is apparent from the following Table.

Inhibitory Effect of Lactobacillus LB21

	<u>Test bacteria</u>	<u>Number</u>	<u>Number inhibited</u>	<u>% inhibition</u>
	E.coli	48	48	100
	Enterococci	41	34	83
5	Group B-			
	streptococci	100	100	100
	Group A-			
	streptococci	5	5	100
	Klebsiella	36	36	100
10	Proteus mir.	16	16	100
	Salmonella	15	15	100
	Shigella	15	15	100
	Ps. aureginosa	15	15	100
	Yersinia	10	10	199
15	Staphylococcus			
	sapro	6	4	67
	Lactobacilli	11	0	0
	H. pylori	3	3	100
	E. coli 0-157	2	2	100
20	Clostridium			
	difficile	5	5	100

The tests were carried out according to the agar layer method as well as in broth. They were repeated and

25 carried out at several different pH values.

Capability of Lactobacillus casei rhamnosus LB21 of inhibiting antibiotic-associated diarrhoea

31 healthy objects participated in the study, 16 men and 15 women. The objects were then divided according to

30 sex and then randomly into test or control group. The test group included 16 objects and the control group 15 objects. The average age in the test group was 24.6 years, in the range 19-31 years. The average age in the control group was 24.4 years, in the range 20-33

35 years. Two objects in the control group dropped out in the course of the study owing to pregnancy and trouble caused by the intake of antibiotics. The dropping out

thus amounted to 6.5%. For the last faeces test, one more object in the control group dropped out owing to a sports injury. None of the objects was smoker or snuff taker or had taken antibiotics during the last six months before the study. No medication except Kåvepenin was allowed in the course of the study. The objects were not allowed to take any fermented products two weeks before the start of the intake of penicillin and in the course of the study. The experiment was carried out as a double blind placebo-controlled test and was approved by the search-ethical committee of the Faculty of Medicine, University of Umeå, Umeå.

The test group as well as the control group took 500 mg Kåvepenin in capsules perorally (phenoxymethylpenicillin potassium, Astra Läkemedel, Södertälje) twice a day for ten days.

The test group was given frozen skim milk with LB21 (Essum, Umeå) at a concentration of  $10^{11}$  cfu (colony-forming units) per ml. The control group was given skim milk as placebo. The objects in the test group took 5 ml of frozen skim milk with LB21 or placebo twice a day. The intake started simultaneously with the penicillin and lasted 15 days.

Samples of faeces were collected before the intake of Kåvepinin on day 0, during the intake of Kåvepenin and LB21 or placebo on day 10 and on day 15 during the intake of LB21/placebo after the completed Kåvepenin cure. The samples were stored in a cold place (+4-8°C) before being delivered to the laboratory where they were frozen and stored at -20°C before analysis. All samples were frozen within 24 h of the sampling.

The objects recorded the number of defecations a day and the consistency of the faeces in a form from one week before the intake of Kåvepenin up to and including five days after the completed cure. Stomach ache and other subjective symptoms were also recorded.

The samples of faeces were weighed and diluted with sterile water at a ratio of 1:10. The pH was measured with indicator paper (Merck, pH 5-10) in the middle of the mixture. LB21 was cultivated after being diluted with sterile water on Rogosa plates with 128 µg of vancomycin. The samples were incubated at 37°C in CO<sub>2</sub> environment for 48 h.

All lactobacilli were cultivated after being diluted with sterile water on Rogosa plates. The samples were anaerobically incubated at 37°C for 48 h. Then the samples were stored at -20°C.

Tests for *Clostridium difficile* toxin were carried out according to Aronsson et al.

The frequency of defecations, consistency of the faeces, stomach ache and other subjective symptoms were recorded, and average, median and range were calculated.

Statistical calculations were carried out with SPSS for Windows. The results were presented as average values and median values. The values of lactobacilli were logarithmated (log 10) before the statistical calculation. The median value and the range between the maximum and minimum value were calculated on the basis of the number of defecations, consistency of the faeces and pH value. Statistical comparisons between the groups, where a normal range was not to be found or was unreliable, were carried out with Mann-Whitney U test (number of defecations, consistency of faeces, lactobacilli, pH). A pH of less than 0.05 was considered statistically significant.

### Results

The objects taking LB21 had considerably fewer defecations/diarrhoea during the intake of phenoxymethyl penicillin compared with the placebo group, viz. 0.24 and 0.98, respectively ( $p < 0.05$ ). Moreover, the frequency of defecations and the occurrence of stomach ache increased to a considerable extent during the penicillin treatment in the placebo group compared with the situation before the intake of the penicillin. There was also a consider-

able increase of the amount of *Lactobacillus casei rham-*  
*nosus* in faeces in the group that had been supplied with  
LB21. There were, however, no considerable differences in  
the frequency of defecations or in respect of the total  
5 number of lactobacilli in the samples of faeces in the  
two groups. Furthermore, there were no cases of *Clostri-*  
*dium difficile* toxin in any of the two groups.

Literature References:

1. Sandine, W.E. 1979. Roles of lactobacillus in the gastrointestinal tract. J. Food Protect. 42, 259-262.
- 5 2. Fuller, R. 1986. Probiotics. J. Appl. Bacteriol. Symp. Suppl. 1S-7S.
3. Gilliland, S.E., Nelson, C.R. och Maxwell, C. 1985. 10 Assimilation of cholesterol by Lactobacillus acidophilus. Appl. Environ. Microbiol. 33, 15-18.
4. Goldin, B.R. and Gorbach, S.L. 1980. Effect of Lacto- 15 bacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochlorid induced intestinal cancer in rats. J. Natl. Cancer. Inst. 64, 263-271.
5. Goldin, B.R. and Gorbach, S.L. 1987. Lactobacillus GG: 20 a new strain with properties favorable for survival, adhesion and antimicrobial activity in the gastrointestinal tract. FEMS Microbiol. Rev. 46, P72.
6. Lessard, M. and Brisson, G.J. 1987. Effect of lacto- 25 bacillus fermentation product on growth immune response and fecal enzyme activity in weaned pigs. Can. J. Anim. Sci. 62, 509-516.
7. Siitonen, S., Vapaatalo, H., Salminen, S., Goldin, A., 30 Saxelin, M., Wikberg, R. and Kirkkola, A-L. 1990. Effect of lactobacillus GG Yoghurt in prevention of antibiotic associated diarrhoea. Annual Med. 22, 57-59.
8. Fernandes, C., Shahani, K. Amer, M. 1987. Therapeutic 35 role of dietary lactobacilli and lactobacilli fermented dairy products. FEMS microbiol. Rew. 46: 343-356.

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

Eva Gråhn,  
Essum AB,  
Glimmervägen 66,  
907 40 Umeå,  
Sweden.

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  Lactobacillus casei rhamnosus L20 OS	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  NCIMB 40564
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by: <div style="margin-top: 10px;"> <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation         </div> (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 11 June 1993 (date of the original deposit)	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: <b>NCIMB Ltd</b> 23 St Machar Drive Aberdeen Scotland UK AB2 1RY	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>Alison Baxter</i> Date: 15 June 1993

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.



Our ref: PAT/54

Your ref:

Date: 15 June 1993

Margareta Linderöth,  
AB Astra Patent Department,  
15185 Södertälje,  
Sweden.



Dear Sir/Madam,

NOTIFICATION OF ACCEPTANCE OF A DEPOSIT FOR THE  
PURPOSES OF PATENT PROCEDURE

Microorganism	Strain Number	NCIMB number
→ Lactobacillus casei rhamnosus	L20_05	NCIMB 40564
Lactobacillus casei rhamnosus	A34	NCIMB 40565
Lactobacillus casei rhamnosus	T46	NCIMB 40566
Lactobacillus casei rhamnosus	B79	NCIMB 40567

I have to inform you that the above designated microorganism(s), received on 11 June 1993 was accepted for deposit for patent purposes on 11 June 1993. You are reminded that you are bound by the terms and conditions of this acceptance set out in the Application Form signed by you\* on 7 June 1993 a copy of which should have been retained by you.

Yours faithfully,

Mrs. Alison J. Baxter

\* Eva Grahn,  
Easum AB,  
Glimmörvägen 5E,  
907 40 Umeå,  
Sweden.

Enc.

23 St. Muckar Drive  
Aberdeen AB21 1RY  
Scotland, UK  
Telephone 0224 273332  
Fax 0224 487658  
Telex 73438 UNYADNG  
E-Mail Telecom Gold/Diatcom  
75:DB10271

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Eva Grahn,  
Essum AB,  
Sjimmervägen 5E,  
307 40 Umeå,  
Sweden

VIABILITY STATEMENT  
issued pursuant to Rule 10.2 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified on the following page

NAME AND ADDRESS OF THE PARTY  
TO WHOM THE VIABILITY STATEMENT  
IS ISSUED

DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name:  Address: AS ABOVE	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 40564  Date of the deposit or of the transfer:  11 June 1993
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 14 June 1993 <sup>2</sup> . On that date, the said microorganism was <input checked="checked" type="checkbox"/> <sup>3</sup> viable <input type="checkbox"/> <sup>3</sup> no longer viable	

Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

<sup>2</sup> In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

<sup>3</sup> Mark with a cross the applicable box.

IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED<sup>4</sup>

## INTERNATIONAL DEPOSITARY AUTHORITY

Name:

ACMB Ltd

Address:

23 St Machar Drive  
Aberdeen Scotland  
UK AB2 1RYSignature(s) of person(s) having the power  
to represent the International Depositary  
Authority or of authorized official(s):*Alison Baxter*

Date: 15 June 1993

<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

## CLAIMS

1. A pharmaceutical preparation for prophylaxis  
5 against and/or treatment of gastrointestinal disorders  
in man and animals, c h a r a c t e r i s e d in that it  
comprises a viable microorganism strain in the form of  
the Lactobacillus casei rhamnosus strain LB21 with the  
accession number NCIMB 40564 and/or one or more variants  
10 thereof with an essentially similar function in at least  
one pharmaceutically acceptable carrier medium, in which  
the microorganism maintains its viability.
2. A pharmaceutical preparation as claimed in claim  
1, c h a r a c t e r i s e d in that the microorganism  
15 strain is present in an amount of  $10^2$ - $10^{12}$  colony-forming  
units per ml of ready-to-use preparation.
3. A pharmaceutical preparation as claimed in claim  
2, c h a r a c t e r i s e d in that the microorganism  
strain is present in an amount of  $10^6$ - $10^{10}$  colony-forming  
20 units per ml of ready-to-use preparation.
4. A pharmaceutical preparation as claimed in claim  
1, c h a r a c t e r i s e d in that the pharmaceutical  
acceptable carrier medium is a soured or fermented milk  
product, preferably sour milk, yoghurt and milk or fruit  
25 juice, ice-cream, soup and fruit drinks.
5. A pharmaceutical preparation as claimed in any  
one of the preceding claims, c h a r a c t e r i s e d  
in that the pharmaceutical acceptable carrier medium is  
a suitable animal feedstuff, preferably whey, dry fodder  
30 or a concentrated suspension, when administering the pre-  
paration according to the invention to animals.
6. A pharmaceutical preparation as claimed in claim  
1, c h a r a c t e r i s e d in that the bacterial strain  
has been added to the carrier medium as a starting cul-  
35 ture and/or to the ready-to-use preparation.

7. A pharmaceutical preparation as claimed in any one of the preceding claims, characterised in that it is present in dry form, such as capsules, tablets or powder, or in the form of a suspension, optionally frozen, preferably NaCl solution, glucose solution or skim milk, together with a pharmaceutically acceptable carrier material.

8. A pharmaceutical preparation as claimed in any one of the preceding claims, characterised in that the *Lactobacillus casei rhamnosus* strain LB21 has been isolated from faeces of an approx. 1-8-day-old baby, preferably an approx. 5-day-old baby.

9. A pharmaceutical preparation as claimed in any one of the preceding claims, characterised in that at least one other *Lactococcus*, *Lactobacillus* or *Bifidobacterium* strain, preferably *Lactococcus lactis* Lla, is also incorporated into the preparation.

10. A pharmaceutical preparation as claimed in any one of the preceding claims for prophylaxis against and/or treatment of antibiotic-associated diarrhoea, *helicobacter* infection in the stomach and in the upper small intestine, tourist diarrhoea, stress-induced gastrointestinal disorders, cytotoxic-induced intestinal influence, allergies in children, constipation and/or for prophylaxis against intestinal infections in children having undergone a liver transplant or been operated for bile duct atresia or in babies that are newborn or prematurely born.

11. A *Lactobacillus casei rhamnosus* strain capable of preventing and/or curing gastrointestinal disorders in man and animals, wherein it has the accession No. NCIMB 40564.

12. A *Lactobacillus casei rhamnosus* strain as claimed in claim 11, wherein it has been isolated from faeces of an approx. 1-8-day-old baby.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01041

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 35/74, C12N 1/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, US PATENTS FULLTEXT, CA, MEDLINE, BIOSIS, EMBASE, DIALINDEX

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Dialog Information Services, file 65, Inside Conferences, Dialog Accession no. 02105717, Inside Conferences Accession no. CN022056031, Haakansson, E.G. et al: "The ability of Lactobacillus casei rhamnosus LB21 to survive in the gastrointestinal tract and to prevent antibiotic associated diarrhoea", VTT SYMPOSIUM, 1997; Vol 173, P: 57-58 --	1-12
X	WO 9301823 A1 (PROBI AB), 4 February 1993 (04.02.93), claims 6-7 --	1-12
X	EP 0271364 A2 (BIOREM C.C.), 14 December 1987 (14.12.87), claim 1 and example 6 --	1-12

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
10 Sept 1998	17 -09- 1998
Name and mailing address of the ISA: Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Carolina Palmcrantz Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01041

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 2421066 A1 (SOLCO BASEL AG), 25 March 1976 (25.03.76), the claims  -- -----	1-12

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

27/07/98

International application No.  
PCT/SE 98/01041

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9301823 A1	04/02/93	AT 164073 T	15/04/98
		AU 659669 B	25/05/95
		AU 2370992 A	23/02/93
		CA 2091557 A	26/01/93
		DE 69224814 D	00/00/00
		EP 0554418 A,B	11/08/93
		SE 0554418 T3	
		ES 2114565 T	01/06/98
		FI 931260 A	22/03/93
		JP 2742962 B	22/04/98
		JP 6501624 T	24/02/94
		SE 469875 B,C	04/10/93
		SE 9102238 A	26/01/93
		US 5474932 A	12/12/95
		US 5587314 A	24/12/96
		US 5591428 A	07/01/97
EP 0271364 A2	14/12/87	NONE	
DE 2421066 A1	25/03/76	NONE	